Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam J Bass

Showing results (31-40 of 121) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|December 4, 2013
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 lossEllen M Beauchamp, Brittany A Woods, Austin M Dulak, et al.
Plos One|April 21, 2017
Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patientsSteven E Schumacher, Byoung Yong Shim, Giovanni Corso, et al.
ACS Medicinal Chemistry Letters|January 25, 2021
Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) InhibitorBrian J Groendyke, Behnam Nabet, Mikaela L Mohardt, et al.
Nature Communications|March 23, 2019
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinomaShuo Qie, Akihiro Yoshida, Stuart Parnham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivityAmy L Silvers, Lin Lin, Adam J Bass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.
JCI Insight|February 8, 2023
Developing SHP2-based combination therapy for KRAS-amplified cancerTianxia Li, Osamu Kikuchi, Jin Zhou, et al.
Oncotarget|May 6, 2016
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersSarah Derks, Xiaoyun Liao, Anna M Chiaravalli, et al.
Cancer Discovery|January 1, 2013
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progressionYufang Wang, Sérgia Velho, Efsevia Vakiani, et al.
Plos One|October 29, 2014
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsYong Sang Hong, Jihun Kim, Eirini Pectasides, et al.
Pageof 13

Showing results (31-40 of 121) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|December 4, 2013
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 lossEllen M Beauchamp, Brittany A Woods, Austin M Dulak, et al.
Plos One|April 21, 2017
Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patientsSteven E Schumacher, Byoung Yong Shim, Giovanni Corso, et al.
ACS Medicinal Chemistry Letters|January 25, 2021
Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) InhibitorBrian J Groendyke, Behnam Nabet, Mikaela L Mohardt, et al.
Nature Communications|March 23, 2019
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinomaShuo Qie, Akihiro Yoshida, Stuart Parnham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivityAmy L Silvers, Lin Lin, Adam J Bass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.
JCI Insight|February 8, 2023
Developing SHP2-based combination therapy for KRAS-amplified cancerTianxia Li, Osamu Kikuchi, Jin Zhou, et al.
Oncotarget|May 6, 2016
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersSarah Derks, Xiaoyun Liao, Anna M Chiaravalli, et al.
Cancer Discovery|January 1, 2013
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progressionYufang Wang, Sérgia Velho, Efsevia Vakiani, et al.
Plos One|October 29, 2014
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsYong Sang Hong, Jihun Kim, Eirini Pectasides, et al.
Pageof 13